Rapamycin vs Metformin

Rapamycin (D-tier) vs Metformin (D-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

Rapamycin · tier D

Rapamycin and sirolimus are the same active substance. Product-specific sirolimus approvals and mouse lifespan results do not establish healthy-human longevity or cognitive benefit.

Dietary rapamycin extended lifespan measures in UM-HET3 mice, but small human aging trials have not established a primary functional, visceral-fat, lifespan, broad healthspan, or cognitive benefit.

-2.13 reps primary ITT chair-stand difference in RAPA-EX-01, p=0.089 · half-life 62 +/- 16 h after multiple systemic oral dosing in stable renal-transplant patients · focus

Metformin · tier D

Metformin is an established type 2 diabetes drug. Its diabetes outcomes do not establish healthy-human lifespan, healthspan, cognition, or muscle benefit, and randomized geroscience trials have been null or unfavorable on their primary claims.

UKPDS supports selected long-term outcomes in overweight people with newly diagnosed type 2 diabetes. MASTERS, MET-PREVENT, and METFORAGING do not establish a general healthy-aging benefit.

0.001 m/s MET-PREVENT walking-speed difference · half-life about 6.2 h in plasma and 17.6 h in blood in the immediate-release label record · focus

at a glance

• Rapamycin: tier D · -2.13 reps primary ITT chair-stand difference in RAPA-EX-01, p=0.089
• Metformin: tier D · 0.001 m/s MET-PREVENT walking-speed difference

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.